Search

Your search keyword '"Turjanmaa K"' showing total 316 results
Start Over Author "Turjanmaa K"
316 results on '"Turjanmaa K"'

3. Natural-Rubber-Latex Allergy

Author

Turjanmaa, K., Alenius, H., Mäkinen-Kiljunen, S., Reunala, T., Palosuo, T., Kanerva, Lasse, editor, Wahlberg, Jan E., editor, Elsner, P., editor, and Maibach, Howard I., editor

Published
2000
Full Text
View/download PDF

12. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report

Author

Akdis, C. A., Akdis, M., Bieber, T., Bindslev-Jensen, C., Boguniewicz, M., Eigenmann, P., Hamid, Q., Kapp, A., Leung, D. Y. M., Lipozencic, J., Luger, T. A., Muraro, A., Novak, N., Platts-Mills, T. A. E., Rosenwasser, L., Scheynius, A., Simons, F. E. R., Spergel, J., Turjanmaa, K., Wahn, U., Weidinger, S., Werfel, T., and Zuberbier, T.

Published
2006

38. Diagnosis and treatment of atopic dermatitis in children and adults:European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Astma, and Immunology/PRACTALL Consensus report

Author

Akdis, C.A., Akdis, M., Bieber, T., Bindslev-Jensen, Carsten, Boguniewicz, M., Eigenmann, P., Hamid, Q., Kapp, A., Leung, D.Y., Lipozencic, J., Luger, T.A., Muraro, A., Novak, N., Platts-Mills, T.A., Rosenwasser, L., Scheynius, A., Simons, F.E., Spergel, J., Turjanmaa, K., Wahn, U., Weidinger, S., Werfel, T., and Zuberbier, T.

Published
2006

40. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.

Author

Remitz, A., Harper, J., Rustin, M., Goldschmidt, W., Palatsi, R., Valk, P.G.M. van der, Sharpe, G., Smith, C.H., Dobozy, A., Turjanmaa, K., Remitz, A., Harper, J., Rustin, M., Goldschmidt, W., Palatsi, R., Valk, P.G.M. van der, Sharpe, G., Smith, C.H., Dobozy, A., and Turjanmaa, K.

Abstract

Contains fulltext : 53193.pdf (publisher's version ) (Open Access), Tacrolimus ointment is a topical calcineurin inhibitor for the treatment of atopic dermatitis. The primary objective of this open-label study was to assess the long-term safety of tacrolimus ointment. The primary end-point was the incidence of adverse events. Secondary end-points included the Eczema Area and Severity Index and a modified version of this index. A total of 466 children with atopic dermatitis, aged 2-15 years, applied 0.03% or 0.1% tacrolimus ointment twice daily for up to 29.5 months. Skin burning and pruritus were the most common application site events; their prevalence decreased over time. There was no increase in viral infections or other adverse events over time. Laboratory profiles were consistent with those reported in atopic populations. Substantial improvement in all efficacy end-points was observed by week 2 and maintained throughout the study. Long-term treatment with tacrolimus ointment is safe and effective in these patients with atopic dermatitis.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results